Study design and patients
allergic, Tumor, cardiopulmonary and coagulation insufficiency, Tumors, unresectable advanced HCC, immunodeficiency disease
TUMORS, TUMOR, MALIGNANT TUMORS, IMMUNODEFICIENCY DISEASE
The prospective study was conducted at five centers in Shandong Province. The study was approved by the Ethics Review Board, and all patients provided written informed consent. All procedures carried out in studies involving human participants complied with the ethical standards of institutional and national research councils, the 1964 Declaration of Helsinki and its subsequent amendments. Eligible patients were aged 18-75 years with unresectable advanced HCC confirmed by histopathology, or diagnostic imaging (CT or MRI) with at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The performance status of the Eastern Cooperative Tumor Group (ECOG) was 0 or 1, and the Child-Pugh classification was A to B. Patients with the following conditions were excluded: 1) existing immunodeficiency disease or a history of organ transplantation; 2) allergic to camrelizumab active ingredients or excipients; 3) those who participated in other clinical trials; 4) severe cardiopulmonary and coagulation insufficiency, which cannot receive combined therapy with TACE plus targeted drugs and camrelizumab; 5) history of other malignant tumors.